{
    "id": 60108,
    "name": "brain glioma",
    "source": "DOID",
    "definition": "A brain cancer that has_material_basis_in glial cells. [url:http\\://cancergenome.nih.gov/cancersselected/lowergradeglioma, url:http\\://www.cancer.gov/dictionary?CdrID=45700]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0060108",
    "evidence": [
        {
            "id": 1078,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Caprelsa (vandetanib), in combination with dasatinib, demonstrated safety in pediatric patients with intrinsic pontine glioma (PMID: 23536435).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1529,
                "therapyName": "Dasatinib + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 813,
                    "pubMedId": 23536435,
                    "title": "Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23536435"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1079,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) decreased cell proliferation and induced apoptosis in mouse models of glioma (PMID: 21926191).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 587,
                    "pubMedId": 21926191,
                    "title": "Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926191"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1085,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) in combination with radiation, reduced survival of cells derived from pediatric patients with high-grade gliomas (PMID: 24305702).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 816,
                    "pubMedId": 24305702,
                    "title": "Targeting Wee1 for the treatment of pediatric high-grade gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24305702"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1441,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Ofev (nintedanib) failed to show any efficacy in patients with recurrent high-grade glioma, regardless of prior bevacizumab therapy (PMID: 25338318).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1283,
                    "pubMedId": 25338318,
                    "title": "Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25338318"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1553,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, dorsomorphin (Compound C) inhibited AMPK and reduced glioma cells viability in vitro by inhibiting proliferation and inducing cell death (PMID: 24419061)",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1863,
                "therapyName": "Dorsomorphin",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1505,
                    "pubMedId": 24419061,
                    "title": "The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24419061"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2186,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioma cells with a loss of NF1 expression were resistant to growth inhibition by Rapamune (sirolimus) (PMID: 21216928).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2720,
                    "pubMedId": 21216928,
                    "title": "Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216928"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3155,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human glioma cells with PTEN loss in culture (PMID: 21325073).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7277,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, treatment with Selumetinib (AZD-6244) resulted in responses in 21% (8/38) of pediatric patients with low-grade gliomas, with 3 responding patients harboring KIAA1549-BRAF fusions (J Clin Oncol 32:5s, 2014 (suppl; abstr 10065)).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6285,
                    "pubMedId": null,
                    "title": "A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report.",
                    "url": "http://meetinglibrary.asco.org/content/134121-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8937,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, inhibition of RPS6KA5 via shRNA combined with DS-7423 in glioma cell line xenograft models resulted in the greatest sensitivity compared to either inhibitory mechanism alone, demonstrating increased survival (PMID: 27196759).",
            "molecularProfile": {
                "id": 26537,
                "profileName": "RPS6KA5 positive"
            },
            "therapy": {
                "id": 722,
                "therapyName": "DS-7423",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6791,
                    "pubMedId": 27196759,
                    "title": "MSK1-Mediated \u03b2-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196759"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18502,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Selumetinib (AZD6244) treatment resulted in a sustained partial response (PR) in 36% (9/25) and stable disease in 60% (15/25) of pediatric patients with NF1-associated low grade glioma, with a 2-year progression-free survival of 96% (PMID: 31151904; NCT01089101).",
            "molecularProfile": {
                "id": 1239,
                "profileName": "NF1 mutant"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16287,
                    "pubMedId": 31151904,
                    "title": "Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151904"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20336,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NT-I7 treatment improved survival in a mouse model of glioma (Journal of Clinical Oncology 37, no. 15_suppl, Abs nr: e13516).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9320,
                "therapyName": "NT-I7",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17810,
                    "pubMedId": null,
                    "title": "Effect of a novel long-acting interleukin-7 agonist, NT-I7, on survival in mouse models of glioma.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e13516"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00602667",
            "title": "Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2449,
                    "therapyName": "Cisplatin + Cyclophosphamide + Methotrexate + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 2450,
                    "therapyName": "Cyclophosphamide + Etoposide + Topotecan",
                    "synonyms": null
                },
                {
                    "id": 2451,
                    "therapyName": "Cyclophosphamide + Erlotinib + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00660621",
            "title": "A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2115,
                    "therapyName": "Bevacizumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00823459",
            "title": "Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01390948",
            "title": "A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01580969",
            "title": "Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01661400",
            "title": "Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1475,
                    "therapyName": "Thalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01672463",
            "title": "Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7151,
                    "therapyName": "OKN-007",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01774253",
            "title": "Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 956,
                    "therapyName": "Vismodegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01967810",
            "title": "ANG1005 in Patients With Recurrent High-Grade Glioma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 2053,
                    "therapyName": "GRN1005",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02124772",
            "title": "Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02372006",
            "title": "Trial of Afatinib in Pediatric Tumours",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03122197",
            "title": "Study of Letrozole in Recurrent Gliomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03363217",
            "title": "Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03429803",
            "title": "TAK-580 In Gliomas and Other Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1034,
                    "therapyName": "MLN2480",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03576612",
            "title": "GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas (GMCI)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4461,
                    "therapyName": "AdV-tk",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 5171,
                    "therapyName": "Valacyclovir",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03796273",
            "title": "Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 2858,
                    "therapyName": "Ketoconazole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03871257",
            "title": "A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8990,
                    "therapyName": "Carboplatin + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                }
            ]
        }
    ]
}